Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04691154 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

A Phase 3 study of Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Diseases, sponsored by Liquidia Technologies.

Active
Registry status
Phase 3
Development phase
28
Enrollment target
8
Study locations

NCT04691154 is a Phase 3 study of Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Diseases that is active but no longer recruiting, run by Liquidia Technologies. The registered enrollment target is 28 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04691154, a Phase 3 study of Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Diseases, is active but no longer recruiting, sponsored by Liquidia Technologies.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
28 participants
Enrollment target
8
Study locations

Study Summary

This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.

Conditions Studied

Pulmonary Arterial Hypertension Pulmonary Hypertension Due to Lung Diseases

Interventions

  • COMBINATION_PRODUCT L606 inhalation suspension

Study Locations (8)

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • University of South Florida - Tampa

Arizona

  • Arizona Pulmonary Specialists - Scottsdale

California

  • VA Greater Los Angeles Healthcare - Los Angeles

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Oregon

  • Summit Health Eastside Clinic - Bend

Texas

  • Baylor Scott and White Research Institute - Temple

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-08-01
Est. Completion 2031-03-31
Phase Phase 3

Sponsor

Liquidia Technologies

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04691154

The ClinicalTrials.gov registry entry for NCT04691154 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The listed sponsor is Liquidia Technologies, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which L606 inhalation suspension is the first listed.

NCT04691154 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT04691154 about?

NCT04691154 is a clinical study titled "A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD". This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.

What is the current status of trial NCT04691154?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2021-08-01. Estimated completion is 2031-03-31.

What conditions does trial NCT04691154 study?

This clinical trial studies the following conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases.

What interventions are being tested in trial NCT04691154?

The interventions under investigation include: L606 inhalation suspension (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT04691154?

This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04691154 being conducted?

This trial has 8 study locations across Arizona, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Arterial Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Arterial Hypertension

All registered trials for this condition

Pulmonary Hypertension Due to Lung Diseases

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.